Venrock Adviser, LLC
CIK
1615982
Location
NEW YORK, NY
Portfolio Value
Mid
$3,298,051,599
Diversification
Moderately concentrated
Filing Date
Global Rank
#1,175
/ 8,794
▲ 31
· as of Jun 2026
Top Industry
Biotechnology
99.9%
Period ended 3 months ago
Filed Aug 14, 2026 · 51d
26 quarters · since Mar 2020
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
33 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Top Position
34.2%
+6.1 pts
Top 5
67.6%
+10.0 pts
Top 10
80.4%
+6.7 pts
HHI
1,543
Moderately concentrated+423
Portfolio Trend
26 quarters · across all stocks
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 99.9% | $3,294,841,599 |
| Financial Services | 0.1% | $3,210,000 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased
5 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| RLMD | Relmada Therapeutics, Inc. | +2,000,925 | 6,844,305 | $47,362,590 | |
| XFOR | X4 Pharmaceuticals, Inc | +1,603,728 | 1,934,253 | $9,032,961 | |
| ERAS | Erasca, Inc. | +1,509,000 | 17,891,812 | $327,777,995 | |
| SVRA | Savara Inc | +1,005,568 | 14,745,943 | $90,835,008 | |
| ARTV | Artiva Biotherapeutics, Inc. | +434,027 | 2,043,596 | $19,822,881 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced
5 positions
| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | −5,000,000 | 4,982,124 | $18,682,965 | |
| ELVN | Enliven Therapeutics, Inc. | −1,200,000 | 526,331 | $26,711,298 | |
| SYRE | Spyre Therapeutics, Inc. | −700,000 | 2,985,448 | $265,048,073 | |
| VRDN | Viridian Therapeutics, Inc.\DE | −624,792 | 3,257,917 | $59,847,935 | |
| COGT | Cogent Biosciences, Inc. | −357,834 | 1,642,166 | $63,551,824 | |
| No positions match the current search. | |||||
New Positions
Positions the filer opened this quarter
4 positions
33 tracked positions ·
$3,298,051,599 total
· filing declares
33 positions · $3,298,051,614
· as of Jun 30, 2026
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
|
|
Held | 8,493,321 | $1,127,318,496 | 34.18% | ||
| ORKA |
Oruka Therapeutics, Inc.
Healthcare
|
Held | 4,148,428 | $394,805,892 | 11.97% | |
| ERAS |
Erasca, Inc.
Healthcare
|
Added | 17,891,812 | $327,777,995 | 9.94% | |
| SYRE |
Spyre Therapeutics, Inc.
Healthcare
|
Reduced | 2,985,448 | $265,048,073 | 8.04% | |
| DNTH |
Dianthus Therapeutics, Inc. /DE/
Healthcare
|
Held | 1,180,000 | $115,026,400 | 3.49% | |
| OCUL |
Ocular Therapeutix, Inc
Healthcare
|
Held | 10,346,926 | $101,606,813 | 3.08% | |
| DMRA |
Damora Therapeutics, Inc.
Healthcare
|
Held | 3,603,595 | $93,729,505 | 2.84% | |
| SVRA |
Savara Inc
Healthcare
|
Added | 14,745,943 | $90,835,008 | 2.75% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
Held | 3,220,364 | $71,556,488 | 2.17% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 1,642,166 | $63,551,824 | 1.93% | |
| VRDN |
Viridian Therapeutics, Inc.\DE
Healthcare
|
Reduced | 3,257,917 | $59,847,935 | 1.81% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Held | 3,041,719 | $55,998,046 | 1.70% | |
| DYN |
Dyne Therapeutics, Inc.
Healthcare
|
Held | 2,173,913 | $48,282,607 | 1.46% | |
| MAZE |
Maze Therapeutics, Inc.
Healthcare
|
Held | 1,602,034 | $47,804,694 | 1.45% | |
| RLMD |
Relmada Therapeutics, Inc.
Healthcare
|
Added | 6,844,305 | $47,362,590 | 1.44% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Held | 4,319,765 | $46,783,054 | 1.42% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 2,133,576 | $38,404,368 | 1.16% | |
| ZURA |
Zura Bio Ltd
Healthcare
|
Held | 6,434,990 | $37,966,441 | 1.15% | |
| ANL |
Adlai Nortye Group Ltd.
Healthcare
|
Held | 3,212,731 | $36,946,406 | 1.12% | |
| ELVN |
Enliven Therapeutics, Inc.
Healthcare
|
Reduced | 526,331 | $26,711,298 | 0.81% | |
| HELP |
Cybin Inc.
Healthcare
|
Held | 3,851,654 | $25,459,432 | 0.77% | |
| CGEM |
Cullinan Therapeutics, Inc.
Healthcare
|
Held | 1,379,965 | $25,129,162 | 0.76% | |
| IPSC |
Century Therapeutics, Inc.
Healthcare
|
Held | 8,695,652 | $21,304,347 | 0.65% | |
| ARTV |
Artiva Biotherapeutics, Inc.
Healthcare
|
Added | 2,043,596 | $19,822,881 | 0.60% | |
| CTMX |
CytomX Therapeutics, Inc.
Healthcare
|
Reduced | 4,982,124 | $18,682,965 | 0.57% | |
| ACHV |
Achieve Life Sciences, Inc.
Healthcare
|
NEW | 2,751,032 | $17,964,238 | 0.54% | |
| PBLS |
Parabilis Medicines, Inc.
Healthcare
|
NEW | 625,000 | $17,106,250 | 0.52% | |
| SRZN |
Surrozen, Inc./DE
Healthcare
|
Held | 632,931 | $16,424,559 | 0.50% | |
| KRRO |
Korro Bio, Inc.
Healthcare
|
Held | 1,009,500 | $13,305,210 | 0.40% | |
| ANRO |
Alto Neuroscience, Inc.
Healthcare
|
Held | 500,000 | $13,195,000 | 0.40% | |
| XFOR |
X4 Pharmaceuticals, Inc
Healthcare
|
Added | 1,934,253 | $9,032,961 | 0.27% | |
| RACC |
Research Alliance Corp III
Financial Services
|
NEW | 300,000 | $3,210,000 | 0.10% | |
| INM |
InMed Pharmaceuticals Inc.
Healthcare
|
NEW | 32,685 | $50,661 | 0.00% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.